GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Total Current Liabilities

Genetic Technologies (Genetic Technologies) Total Current Liabilities : $2.29 Mil (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Genetic Technologies's total current liabilities for the quarter that ended in Dec. 2023 was $2.29

Genetic Technologies Total Current Liabilities Historical Data

The historical data trend for Genetic Technologies's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Total Current Liabilities Chart

Genetic Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.04 0.97 1.07 2.68 2.22

Genetic Technologies Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.86 - 2.22 - 2.29

Genetic Technologies Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Genetic Technologies's Total Current Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.085+0.204
+Other Current Liabilities+Current Deferred Liabilities
=0.364+0.57
=2.22

Genetic Technologies's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.283+0.199
+Other Current Liabilities+Current Deferred Liabilities
=0.297+0.511
=2.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Genetic Technologies Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (Genetic Technologies) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Total Current Liabilities
Comparable Companies
ASX:RHY ASX:BDX ASX:LDX ASX:IBX ASX:CTE ASX:IIQ TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN WAT SHSE:603259 LH DGX
Traded in Other Exchanges
DU8:Germany GTG:Australia
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Website
https://www.gtglabs.com
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.